News
Efficacy and Safety of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction
Previous studies have shown that the antidiabetic drug empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with reduced left ventricular ejection fraction (HFrEF), both in diabetics and non-diabetics. The aim of the EMPEROR-Preserved clinical trial was to supplement data on the efficacy and safety of empagliflozin in a population of patients with heart failure with preserved ejection fraction (HFpEF; EF LK > 40%).
Brentuximab Vedotin in Patients with R/R cHL in the Real World: What to Expect?
How does brentuximab vedotin (BV) perform as maintenance therapy in real-world practice for…
What Response to the COVID-19 Vaccine Can Be Expected in Patients After Stem Cell Transplantation?
During the recent virtual congress of the European Society for Blood and Marrow Transplantation…
News in the Treatment of Allergic Rhinitis
According to literary sources, 17–28.5% of Europeans suffer from allergic rhinitis (AR), which…
Benefits of Combining Olopatadine and Mometasone in the Treatment of Allergic Rhinitis
Ryaltris is indicated for adults and adolescents aged 12 years and older for the treatment of…
Efficacy and Safety of Fixed Combination of Olopatadine and Mometasone in Nasal Spray for Treatment of Seasonal Allergic Rhinitis
Patients with allergic rhinitis require medications with rapid onset and long duration of action.…
Luck in Unluckiness: Influence of Anticoagulant Therapy on Severity of Stroke in Atrial Fibrillation
A recent Swiss study evaluated the severity, complications, and outcomes of cerebrovascular…
Gliflozins Successfully Treat Type 2 Diabetes Mellitus and Heart Failure
The number of patients with type 2 diabetes mellitus (DM2) and heart failure is increasing…
New Drug in the Biologic Therapy Arsenal for Plaque Psoriasis
Bimekizumab shows promising effects in clinical studies with psoriasis patients. Let's take a…
Ceftaroline vs. Vancomycin in the Treatment of Acute Pulmonary Exacerbation of Cystic Fibrosis
Up to 25% of patients with cystic fibrosis are colonized with methicillin-resistant Staphylococcus…